comprehensive -WSS

comprehensive

author：entertainment 2025-08-26 10:52:33 - browse：6778

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Rare Northern Lights show in US this week: Where and how to see it

hotspot

WSS

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Let's speed up science by embracing open access publishing

Cord blood banking comes at a high cost to babies

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

hotspot

comprehensive

knowledge

In age of alternative facts, a scholarly course on calling out crap

ASCO: Palliative care found as helpful given virtually as in person

Peter Hotez and the public health issue of online harassment

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

In age of alternative facts, a scholarly course on calling out crap

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Medical records are filled with copy

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

After affirmative action ruling, medical educators look to 'holistic review'

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

leisure time

Ultragenyx gene therapy for rare liver ailment succeeds in late

With trial win, GSK could get blood cancer drug back on market

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Drinking water from half of US faucets contains PFAS: Study

What to know about a major upcoming Wegovy heart health study

How to increase colonoscopy rates? Looks like an AI can help

hotspot

hotspot

hotspot

Wikipedia